IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells

BACKGROUND: ICIs have strongly improved the outcome of NSCLC patients. However, primary and secondary resistance occur during treatment in most of the patients, with several of them developing fast progressions. Autoantibodies can be related with a dysfunctional immune system, although their associa...

詳細記述

保存先:
書誌詳細
出版年:EBioMedicine
主要な著者: Ugolini, Alessio, Zizzari, Ilaria Grazia, Ceccarelli, Fulvia, Botticelli, Andrea, Colasanti, Tania, Strigari, Lidia, Rughetti, Aurelia, Rahimi, Hassan, Conti, Fabrizio, Valesini, Guido, Marchetti, Paolo, Nuti, Marianna
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2020
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7658668/
https://ncbi.nlm.nih.gov/pubmed/33166793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103098
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料